Literature DB >> 28604482

Azithromycin Efficacy in Asymptomatic Rectal Chlamydial Infection in Men Who Have Sex With Men: A More Definitive Answer Soon?

Byron E Batteiger1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28604482      PMCID： PMC5470085          DOI： 10.1097/OLQ.0000000000000639

Source DB:  PubMed          Journal:  Sex Transm Dis        ISSN： 0148-5717            Impact factor:   2.830


× No keyword cloud information.
  15 in total

1.  2010 European guideline for the management of Chlamydia trachomatis infections.

Authors:  E Lanjouw; J M Ossewaarde; A Stary; F Boag; W I van der Meijden
Journal:  Int J STD AIDS       Date:  2010-11       Impact factor: 1.359

2.  Sexually transmitted diseases treatment guidelines, 2015.

Authors:  Kimberly A Workowski; Gail A Bolan
Journal:  MMWR Recomm Rep       Date:  2015-06-05

Review 3.  The efficacy of azithromycin and doxycycline for the treatment of rectal chlamydia infection: a systematic review and meta-analysis.

Authors:  Fabian Yuh Shiong Kong; Sepehr N Tabrizi; Christopher Kincaid Fairley; Lenka A Vodstrcil; Wilhelmina M Huston; Marcus Chen; Catriona Bradshaw; Jane S Hocking
Journal:  J Antimicrob Chemother       Date:  2015-01-29       Impact factor: 5.790

4.  Comparing azithromycin and doxycycline for the treatment of rectal chlamydial infection: a retrospective cohort study.

Authors:  Christine M Khosropour; Julia C Dombrowski; Lindley A Barbee; Lisa E Manhart; Matthew R Golden
Journal:  Sex Transm Dis       Date:  2014-02       Impact factor: 2.830

5.  Measured versus self-reported compliance with doxycycline therapy for chlamydia-associated syndromes: high therapeutic success rates despite poor compliance.

Authors:  L H Bachmann; J Stephens; C M Richey; E W Hook
Journal:  Sex Transm Dis       Date:  1999-05       Impact factor: 2.830

6.  Compliance with doxycycline therapy in sexually transmitted diseases clinics.

Authors:  M Augenbraun; L Bachmann; T Wallace; L Dubouchet; W McCormack; E W Hook
Journal:  Sex Transm Dis       Date:  1998-01       Impact factor: 2.830

7.  Biological and Behavioral Factors Associated With Positive Chlamydia Retests.

Authors:  Kirsty S Smith; Rebecca Guy; Jennifer Danielewski; Sepehr N Tabrizi; Christopher K Fairley; Anna M McNulty; William Rawlinson; Marion Saville; Suzanne M Garland; Basil Donovan; John M Kaldor; Jane S Hocking
Journal:  Sex Transm Dis       Date:  2017-07       Impact factor: 2.830

Review 8.  Hidden in plain sight: chlamydial gastrointestinal infection and its relevance to persistence in human genital infection.

Authors:  Roger G Rank; Laxmi Yeruva
Journal:  Infect Immun       Date:  2014-01-13       Impact factor: 3.441

9.  Extragenital gonorrhea and chlamydia testing and infection among men who have sex with men--STD Surveillance Network, United States, 2010-2012.

Authors:  Monica E Patton; Sarah Kidd; Eloisa Llata; Mark Stenger; Jim Braxton; Lenore Asbel; Kyle Bernstein; Beau Gratzer; Megan Jespersen; Roxanne Kerani; Christie Mettenbrink; Mukhtar Mohamed; Preeti Pathela; Christina Schumacher; Ali Stirland; Jeff Stover; Irina Tabidze; Robert D Kirkcaldy; Hillard Weinstock
Journal:  Clin Infect Dis       Date:  2014-03-18       Impact factor: 9.079

10.  Treatment efficacy of azithromycin 1 g single dose versus doxycycline 100 mg twice daily for 7 days for the treatment of rectal chlamydia among men who have sex with men - a double-blind randomised controlled trial protocol.

Authors:  Andrew Lau; Fabian Kong; Christopher K Fairley; Basil Donovan; Marcus Chen; Catriona Bradshaw; Mark Boyd; Janaki Amin; Peter Timms; Sepehr Tabrizi; David G Regan; David A Lewis; Anna McNulty; Jane S Hocking
Journal:  BMC Infect Dis       Date:  2017-01-06       Impact factor: 3.090
View more
  1 in total

1.  Chlamydia muridarum Genital and Gastrointestinal Infection Tropism Is Mediated by Distinct Chromosomal Factors.

Authors:  Sandra G Morrison; Amanda M Giebel; Evelyn C Toh; Horace J Spencer; David E Nelson; Richard P Morrison
Journal:  Infect Immun       Date:  2018-06-21       Impact factor: 3.441
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.